STOCK TITAN

Glaukos (NYSE: GKOS) amends Form 4, sets option strike at $106.52

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Glaukos Corp director Aimee S. Weisner received a grant of 2,987 stock options as director compensation. The options have an exercise price of $106.52 per share, were granted on May 28, 2026, and vest in full on the one-year anniversary of the grant date. They are scheduled to expire on May 28, 2036. This amended Form 4 corrects an earlier filing that had reported the exercise price incorrectly, and reflects a routine equity award rather than an open-market stock purchase or sale.

Positive

  • None.

Negative

  • None.
Insider WEISNER AIMEE S
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 2,987 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 2,987 shares (Direct, null)
Footnotes (1)
  1. This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above. Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date.
Options granted 2,987 options Stock Option (Right to Buy) granted May 28, 2026
Exercise price $106.52 per share Corrected exercise price for options granted May 28, 2026
Expiration date May 28, 2036 Option term end for director grant
Shares underlying options 2,987 shares Underlying Glaukos common stock for this option grant
Holdings after transaction 2,987 options Total derivative holdings following this grant
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"The correct exercise price for the options granted is $106.52"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Director Compensation Policy financial
"Granted pursuant to the Issuer's Director Compensation Policy."
vests in full financial
"Vests in full on the one-year anniversary of grant date."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WEISNER AIMEE S

(Last)(First)(Middle)
C/O GLAUKOS CORPORATION
ONE GLAUKOS WAY

(Street)
ALISO VIEJO CALIFORNIA 92656

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
GLAUKOS Corp [ GKOS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
06/01/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$106.52(1)05/28/2026A2,98705/28/2027(2)05/28/2036Common Stock2,987$02,987D
Explanation of Responses:
1. This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above.
2. Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date.
Diana Scherer, Attorney-in-Fact06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Glaukos (GKOS) report in this amended Form 4?

Glaukos reported that director Aimee S. Weisner received a grant of 2,987 stock options. These options are part of her director compensation and represent a right to buy Glaukos common stock at a fixed exercise price in the future.

Why was this Glaukos (GKOS) Form 4 amended?

The Form 4 was amended to correct the exercise price of the options granted on May 28, 2026. A prior filing listed a different price; this amendment clarifies the correct exercise price as $106.52 per share for the awarded options.

What are the key terms of Aimee Weisner’s Glaukos (GKOS) stock option grant?

Aimee Weisner received 2,987 stock options with an exercise price of $106.52 per share. The options were granted on May 28, 2026, vest in full on the one-year anniversary of that date, and are scheduled to expire on May 28, 2036 if not exercised.

Is Aimee Weisner’s Glaukos (GKOS) option grant an open-market purchase or sale?

The transaction is not an open-market purchase or sale. It is a grant of stock options classified as a derivative security, awarded under Glaukos’ director compensation policy, giving her the right to buy shares later at a fixed exercise price.

How many Glaukos (GKOS) options does Aimee Weisner hold after this grant?

After this grant, Aimee Weisner holds 2,987 stock options directly, according to the filing. These options relate to Glaukos common stock and represent her entire reported derivative position in this specific Form 4 amendment.